* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for China Biologic Products Holdings's PEG Ratio or its related term are showing as below:
CBPO'
s PEG Ratio Range Over the Past 10 Years
Min: 3.59 Med: 16.11 Max: 475.5
Current: 55.43
During the past 13 years, China Biologic Products Holdings's highest PEG Ratio was 475.50. The lowest was 3.59. And the median was 16.11.
CBPO's PEG Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.58
vs CBPO: 55.43
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
China Biologic Products Holdings PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of China Biologic Products Holdings's PEG Ratio
For the Biotechnology subindustry, China Biologic Products Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biologic Products Holdings's PEG Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's PEG Ratio distribution charts can be found below:
* The bar in red indicates where China Biologic Products Holdings's PEG Ratio falls into.
China Biologic Products Holdings PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
China Biologic Products Holdings (NAS:CBPO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
China Biologic Products Holdings PEG Ratio Related Terms
Thank you for viewing the detailed overview of China Biologic Products Holdings's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
China Biologic Products Holdings (China Biologic Products Holdings) Business Description
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBPO has been successfully added to your 